Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study

BMJ Open Diabetes Research & Care
Yumie TakeshitaShuichi Kaneko

Abstract

We determined the feasibility of substituting sitagliptin or mitiglinide for bolus insulin injection therapy in patients with type 2 diabetes. 60 patients with type 2 diabetes were enrolled and randomized to switch from mealtime dosing of a rapid-acting insulin analog to either sitagliptin or mitiglinide for 16 weeks. Body weight, body mass index, and waist circumference decreased significantly in both groups at the end of the study. Mitiglinide significantly increased fasting plasma glucose (FPG) levels at the end of the study from 146.5±36.3 to 168.0±38.8 mg/dL, whereas sitagliptin did not affect FPG. Glycated hemoglobin (HbA1c) and 1,5-anhydroglucitol increased significantly in both groups. The C peptide immunoreactivity (CPR) responses after arginine were diminished in both groups. γ-GTP and triglycerides increased, and high-density lipoprotein cholesterol and adiponectin decreased, in the sitagliptin group, but not in the mitiglinide group. Mean Diabetes Treatment Satisfaction Questionnaire scores improved significantly in both groups. Patients whose mean total daily doses of rapid-acting insulin analog were 16.6 and 17.8 units were switched to sitagliptin and mitiglinide, respectively, without a change in the HbA1c level....Continue Reading

References

Apr 1, 1989·Metabolism: Clinical and Experimental·S el BoustaniA Crastes de Paulet
Dec 22, 1999·Neurology·A OttM M Breteler
Jul 21, 2000·The Journal of Clinical Endocrinology and Metabolism·A KatzM J Quon
Oct 3, 2001·American Journal of Epidemiology·J A LuchsingerR Mayeux
Jun 25, 2002·Annals of the New York Academy of Sciences·B VessbyA Andersson
Aug 14, 2002·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·S Del Prato
Oct 13, 2004·Neurology·Jose A LuchsingerRichard Mayeux
Jul 15, 2006·Experimental Gerontology·Arnab MukhopadhyayHeidi A Tissenbaum
Jun 19, 2007·The American Journal of Gastroenterology·Takuya KomuraShuichi Kaneko
Jul 12, 2007·JAMA : the Journal of the American Medical Association·Renee E AmoriAnastassios G Pittas
Nov 14, 2007·Metabolism: Clinical and Experimental·Yuki KitaShuichi Kaneko
Sep 6, 2008·Prostaglandins, Leukotrienes, and Essential Fatty Acids·G SartoreD Fedele
Dec 23, 2008·Diabetes Research and Clinical Practice·Viswanathan MohanKeith D Kaufman
Mar 17, 2010·The New England Journal of Medicine·William C CushmanFaramarz Ismail-Beigi
Nov 30, 2011·Current Opinion in Lipidology·Janine Kröger, Matthias B Schulze
Apr 18, 2013·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Jordi Mayneris-PerxachsUNKNOWN for PREDIMED Study Investigators
Jul 25, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Joel M NeutelChetan S Karyekar
Sep 1, 2014·Metabolism: Clinical and Experimental·Satoshi ImamuraMasaaki Inaba

❮ Previous
Next ❯

Citations

Nov 25, 2016·Lipids in Health and Disease·Xin LiuGeorge Liu
Aug 30, 2018·Journal of Diabetes Investigation·Yumie TakeshitaToshinari Takamura

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Related Feeds

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.